Swiss Medica Provides Revenue Guidance for 2005
Monday February 14, 9:03 am ET
TORONTO--(BUSINESS WIRE)--Feb. 14, 2005--Swiss Medica Inc. (OTCBB:SWME - News) -
"We now have sufficient data, based upon recent sales of the O24 Essential Oil Pain Neutralizer in the U.S. and Canada, that we can present guidance for FY2005," announced Chief Executive Officer, Raghu Kilambi. "For the twelve-month period, ending 31 December 2005, Swiss Medica expects organic net revenues for the Company's Flagship O24 Essential Oil Pain Neutralizer, to be between US$12 and US$14 million. We also expect to report positive EBITDA in the fourth quarter of 2005."
"We are delighted with the exponential sales growth anticipated during 2005," said Mr. Kilambi. "Swiss Medica has found a loyal customer base, which prefers the O24 Essential Oil Pain Neutralizer over competitive external and internal pain relief products. Concrete evidence describes a broad acceptance of the O24 pain reliever by some of North America's largest retailers, and confirms an ongoing success story for our US-patented all natural product.
Swiss Medica defines EBITDA as earnings before interest, taxes, depreciation, amortization, and with other non-cash charges. EBITDA is expected to turn positive in the fourth quarter of 2005 as Swiss Medica continues to aggressively re-invest in the proven marketing strategies, which brought about the instantaneous acceptance of, and rapid sales growth for, the O24 pain relief product.
"We will continue to rely upon the dependable marketing and PR strategies, which are now building the popular O24 brand," said Mr. Kilambi. "Our revenue projections do not include the launch of related pain relief products, or any acquisitions, during this twelve-month period. We expect to provide additional guidance, after we review the results of our multi-media campaign which commences in the very near future."
About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com
Swiss Medica's flagship product, the O24(TM) Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24(TM) pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24(TM) is widely available throughout Canada in leading pharmacies and natural food stores. It is currently available in Happy Harry's Discount Drugstores in the United States, or by visiting www.O24zone.com, for ordering details and store locators.
